Publish in this journal
Journal Information
Vol. 68. Issue 8.
Pages 726-728 (August 2015)
Scientific letter
DOI: 10.1016/j.rec.2015.03.012
Full text access
Idiopathic Dilated Cardiomyopathy Treated With Intracoronary Infusion of Autologous Bone Marrow Cells: Long-term Follow-up
Miocardiopatía dilatada idiopática tratada con infusión intracoronaria de células autólogas de médula ósea: seguimiento a largo plazo
Flor Baeza Garzóna,
Corresponding author

Corresponding author:
, Miguel Romeroa, Javier Suárez de Lezoa, Soledad Ojeda Pinedaa, Concepción Herrerab, José Suárez de Lezoa
a Servicio de Cardiología, Hospital Universitario Reina Sofía, Córdoba, Spain
b Servicio de Hematología, Hospital Universitario Reina Sofía, Córdoba, Spain
This item has received
(Daily data update)
Article information
Full Text
Download PDF
Figures (1)
Tables (1)
Table. Baseline Clinical and Echocardiographic Parameters
Full Text
To the Editor,

Various studies have shown improved left ventricular ejection fraction (LVEF) in ischemic heart disease following infusion of autologous mononuclear bone marrow cells.1,2 There is little information on the long-term results of this approach in nonischemic dilated cardiomyopathy.3–5 Our objective was to analyze the long-term results, as well as the clinical angiographic, echocardiographic, and biological factors associated with good outcomes.

The present study involved a mean follow-up of 53±14 months in 27 patients with dilated cardiomyopathy in optimal clinical treatment and with symptomatic heart failure who underwent intracoronary infusion of autologous mononuclear bone marrow cells between 2008 and 2010. All patients were participants in the TCMR0007/06 trial. Baseline characteristics have been described in a publication from our group.6

The baseline clinical, echocardiographic, hemodynamic (Table), and biological data6 were analyzed to evaluate their influence on late response.


Baseline Clinical and Echocardiographic Parameters

  Group I (n=15)  Group II (n=12)  P 
Age, mean±SD, y  49±12  58±11  <.05 
Men, %  73  75  NS 
NYHA  2.2±0.4  2.7±0.7  <.05 
BNP, pg/mL  341±415  481±424  NS 
Cholesterol, mg%  167±47  183±28  NS 
LDL-C, mg%  99±30  115±19  NS 
HDL-C, mg%  37±10  36±13  NS 
Triglycerides, mg%  145±107  168±108  NS 
Hypertension, %  53  58  NS 
Hyperlipidemia, %  60  75  NS 
Smoking, %  73  58  NS 
Diabetes mellitus, %  27  50  NS 
LVEF, %  30±23±<.05 
LV end-diastolic volume, mL  164±78  214±64  NS 
LV end-systolic volume, mL  112±52  165±56  <.05 
Degree of mitral regurgitation  0.53±0.7  0.50±0.5  NS 
LVEF in sinus rhythm, %  31±24±<.05 
LVEF in sinus rhythm post-PVC, %  46±13  35±11  <.05 
Sinus end-diastolic volume, mL/m2  143±49  183±76  <.05 
Post-PVC end-diastolic volume, mL/m2  163±48  194±74  NS 
End-systolic sinus volume, mL/m2  99±41  142±64  NS 
Post-PVC end-systolic volume, mL/m2  90±40  127±60  NS 
Systolic pressure of the pulmonary artery, mmHg  34±18  37±13  NS 

BNP, brain natriuretic peptide; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; LV, left ventricle; LVEF, LV ejection fraction; NS, no significant; NYHA, New York Heart Association functional class; post-PVC, post-premature ventricular contraction.

All echocardiographic parameters were determined using the Simpson method.

Group I: patients without follow-up events. Group II: patients with follow-up events.

Data are expressed as mean±standard deviation and as percentages; P<.05 was considered statistically significant.

Fifteen patients (56%) showed no major events (group I) and 12 (44%) did (group II). Patients were considered responders if their LVEF had improved more than 5% at the 6-month angiographic evaluation; 21 patients were responders (14 from group I) and 6 were nonresponders (5 from group II).6 The events in group II were as follows: 3 deaths (due to heart failure), 2 at 21 months and 1 at 69 months (a cardiac resynchronization device was implanted in this patient at 18 months after the infusion); 3 patients were admitted at least once due to heart failure (29±11 months); and 6 patients required cardiac resynchronization therapy (25±7 months). After various admissions for heart failure, 1 of the patients with a cardiac resynchronization device received a heart transplant (41 months). All group I patients were in functional class I-II, whereas most of those in group II were in functional class II-III (1.6±0.6 in group I vs 2.3±0.9 in group II; P<.05). The lastnatriuretic peptide value was 156±450 pg/mL (69±58 pg/mL in group I vs 280±750 pg/mL in group II; P<.05). The mean of the last LVEF by transthoracic echocardiography was 35%±13% (42%±11% in group I vs 26%±5% in group II; P<.05), with a global LVEF gain (follow-up LVEF minus baseline LVEF) of 7.4%±11% (11.6%±12.1% in group I vs 2.5%±7.4% in group II; P<.05). There were no differences in cell biological parameters or adverse events directly associated with the treatment.

Differences were found in age (48±11 years in group I vs 58±11 years in group II; P<.05); baseline echocardiogram, with lower mean baseline systolic volume (112±52mL in group I vs 165±56mL in group II; P<.05) and higher LVEF (30%±5% in group I vs 23%±9% in group II; P<.05) and baseline angiogram, with higher LVEF and post-premature ventricular contraction LVEF (31%±9% vs 24%±7%; P<.05; and 46%±13% vs 35%±11%; P<.05) and lower diastolic volume (143±49 mL/m2 in group I vs 183±76mL/m2 in group II; P<.05). Group I had a better baseline New York Heart Association functional class (2.1±0.4 vs 3.0±0.7; P<.05).

At 5 years follow-up, 43% of patients were free of major events. At 6 months, 52% of responders were event-free; at 5 years, only 17% of the nonresponders were event-free. Benefits appeared to be maintained over time, with a 69% 5-year survival rate (Figure). In previous series of nonischemic dilated cardiomyopathy patients treated with conventional therapy, the 5-year survival varied between 55% and 65%. In our series, more than half of the patients with idiopathic dilated cardiomyopathy treated with infusion of autologous mononuclear bone marrow cells showed a favorable clinical course 5 years later and were in functional class I-II and free of major events. A better late clinical course was shown by younger patients, in better clinical condition, with smaller ventricular diameters and better baseline LVEF. Infusion of these cells can be considered a promising and safe therapy because there were no adverse events related to the therapy in our series. However, the results of our study should be carefully interpreted due to the lack of a control group.


Probability of event-free survival, 5-year survival, and changes in left ventricular ejection fraction at 5 years.



B.E. Strauer, G. Steinhoff.
10 years of intracoronary and intramyocardial bone marrow stem cell therapy of the heart: from de methodological origin to clinical practice.
J Am Coll Cardiol., 58 (2011), pp. 1095-1104
J. Suárez de Lezo, C. Herrera, M.A. Romero, M. Pan, R. Jiménez, D. Carmona, et al.
Recuperación funcional tras infusión intracoronaria de células mononucleadas de médula ósea autóloga en pacientes con infarto crónico anterior y depresión severa de la función ventricular.
Rev Esp Cardiol., 63 (2010), pp. 1127-1135
B. Vrtovec, G. Poglajen, M. Sever, L. Lezaic, D. Domanovic, P. Cernelc, et al.
Effects of intracoronary stem cell transplantation in patients with dilated cardiomyopathy.
J Card Fail., 17 (2011), pp. 272-281
B. Vrtovec, G. Poglajen, L. Lezic, M. Sever, D. Domanovic, P. Cernelc, et al.
Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up.
Circ Res., 112 (2013), pp. 165-173
S. Seth, B. Bhargava, R. Narang, R. Ray, S. Mohanty, G. Gulati, AIIMS Stem Cell Study Group, et al.
The ABCD (Autologous Bone Marrow Cells in Dilated Cardiomyopathy) trial — A long-term follow-up study.
J Am Coll Cardiol., 55 (2010), pp. 1643-1644
J. Suárez de Lezo, C. Herrera, M. Romero, M. Pan, Suárez de Lezo Jr., M.D. Carmona, et al.
Mejoría funcional en pacientes con miocardiopatía dilatada tras la infusión intracoronaria de células mononucleares autólogas de médula ósea.
Rev Esp Cardiol., 66 (2013), pp. 450-457
Copyright © 2015. Sociedad Española de Cardiología
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?